1,236
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Smokeless tobacco: is it really safe?

, MBBS, MCFP(SA), MMed(Fam Med) & , MBBS, FCFP(SA), MFamMed, FACTM, FACRRM, FAFP(SA)
Pages 292-295 | Published online: 15 Aug 2014

References

  • Sapundzhiev N, Werner JA. Nasal snuff: historical review and health related aspects. J Laryngol Otol. 2003 Sep; 117(9): 686–91
  • Wyckham RG. Smokeless tobacco in Canada: deterring market development. Tobacco Control 1999; 8: 411–20.
  • McNeil A. Harm reduction. BMJ 2004; 328: 885–7.
  • Mitchell BE, Sobel HL, Alexander MH. The adverse health effects of tobacco and tobacco-related products. Primary Care 1999; 26(3): 463–98.
  • Siegel D, Benowitz N, Ernster VL, Grady DG, Hauck WW. Smokeless tobacco, cardiovascular risk factors, and nicotine and cotinine levels in professional baseball players. Am J Public Health 1992; 82(3): 417–21.
  • Fagerstrom KO, Schildt E. Should the European Union lift the ban on snus? Evidence from the Swedish experience. Addiction 2003; 98(9): 1191–5.
  • Asplund K. Snuff—how dangerous is it? The controversy continues. J Intern Med 2001; 250: 457–61.
  • Asplund K. Smokeless tobacco and cardiovascular disease. Progress in cardiovascular diseases. 2003; 45(5): 383–94.
  • Lee PN. Circulatory disease and smokeless tobacco in Western populations: a review of the evidence. International Journal of Epidemiology 2007; 36(4): 789–804.
  • Ayo-Yusuf OA, Swart TJP, Pickworth WB. Nicotine delivery capabilities of smokeless tobacco products and implications for control of tobacco dependence in South Africa. Tobacco Control 2004; 13: 186–9.
  • Ayo-Yusuf OA, Reddy PS, Van de Borne BW. Association of snuff use with chronic bronchitis among South African women: implications for tobacco harm reduction. Tobacco Control 2008; 17: 99–104.
  • Albert M, Urdal P, Steyn K, et al. Prevalence of cardiovascular diseases and associated risk factors in a rural black population of South Africa. European Journal of Cardiovascular Prevention and Rehabilitation 2005; 12: 347–354.
  • Bates C, Fagerstrom K, Jarvis MJ, Kunze M, McNeil A, Ramstrom L. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tobacco Control 2003; 12: 360–7.
  • Fant RV, Henningfield JE, Nelson RA, Pickworth WB. Pharmacokinetics and pharmacodynamics of moist snuff in humans. Tobacco Control 1999; 8: 387–92.
  • Schroeder KL, Chen MS. Smokeless tobacco and blood pressure. The New England Journal of Medicine 1985; 312(14): 919
  • Rosendahl KI, Galanti MR, Gilljam H, Ahlbom A. Smoking mothers and snuffing fathers: behavioural influences on youth tobacco use in a Swedish cohort. Tobacco Control 2003; 12: 74–8.
  • Burke GL, Hunter SM, Croft JB, Cresanta JL, Berenson GS. The interaction of alcohol and tobacco use in adolescents and young adults: Bogausa heart study. Addictive Behaviors 1988; 13: 387–93.
  • Wickholm S, Galanti MR, Soder B, Giljam H. Cigarette smoking, snuff use and alcohol drinking: co-existing risk behaviours for oral health in young males. Community Dentistry and Oral Epidemiology 2003; 31(4): 269–74.
  • Steyn K, De Wet T, Saloojee Y, Nel H, Yach D. The influence of maternal cigarette smoking, snuff use and passive smoking on pregnancy outcomes: Birth To Ten Study. Paediatr Perinat Epidemiol 2006; 20(2): 90–9.
  • Benowitz NL. Cigarette smoking and cardiovascular disease: pathophysiology and implications for treatment. Progress in Cardiovascular Disease 2003; 46(1): 91–111.
  • Morris DJ, Davis E, Latif SA. Licorice, tobacco chewing and hypertension. The New England Journal of Medicine 1990; 322(12): 849.
  • Jimenez-Ruiz C, Kunze M, Fagerström KO. Nicotine replacement: a new approach to reducing tobacco-related harm. Eur Respir J 1998; 11: 473–9.
  • Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax 2003; 58: 435–43.
  • Bolinder G, De Faire U. Ambulatory 24-h blood pressure monitoring in healthy, middle-aged smokeless tobacco users, smokers, and nontobacco users. Am J Hypertens 1998; 11(10): 1153–63.
  • McPhaul M, Punzi HA, Sandy A, et al. Snuff-induced hypertension in pheochromocytoma. JAMA 1984; 252(20): 2860.
  • Westman EC, Guthrie GP. Blood pressure, plasma rennin activity, aldosterone, and electrolyte values in men using smokeless tobacco. The New England Journal of Medicine 1990; 322(12): 850.
  • Ayo-Yusuf OA, Omole OB. Snuff use and the risk for hypertension among black South African women. SA Fam Pract 2008; 50(2): 64.
  • Persson PG, Carlsson S, Svanstrom L, Ostenson CG, Efendic S, Grill V. Cigarette smoking, oral moist snuff use and glucose intolerance. Journal of Internal Medicine 2000; 248: 103–10.
  • Norberg M, Stenlund H, Lindahl B, Boman K, Weinehall L. Contribution of Swedish moist snuff to the metabolic syndrome: a wolf in sheep's clothing? Scand J Public Health 2006; 34(6): 576–83.
  • Eliason M, Asplund K, Nasic S, Rodu B. Influence of smoking and snus on the prevalence and incidence of type 2 diabetes among men: the northern Sweden MONICA study. J Intern Med. 2004; 256(2): 101–110.
  • Huhtasaari F, Asplund K, Lundberg V, Stegmayr B, Wester PO. Tobacco and myocardial infarction: is snuff less dangerous than cigarettes? BMJ 1992; 305: 1252–6.
  • Bolinder G, Alfredsson L, Englund A, De Faire U. Smokeless tobacco and increased cardiovascular mortality among Swedish construction workers. American Journal of Public Health 1994; 84(3): 399–404.
  • Beaglehole R, Bonita R, Kjellstrom T. Basic epidemiology 2003; WHO, Geneva: 119.
  • Eliasson M, Lundblad D, Hagg E. Cardiovascular risk factors in young snuff-users and cigarette smokers. Journal of Internal Medicine 1991; 230(1): 17–22.
  • Allen SS, Hatsukami D, Jensen J, Grillo M, Bliss R. Effects of treatment on cardiovascular risk among smokeless tobacco users. Preventive Medicine 1995; 24: 357–62.
  • Wallenfeldt K, Hulthe J, Bokemark L, Wikstrand J, Fagerberg B. Carotid and femoral artherosclerosis, cardiovascular risk factors and C-reactive protein in relation to smokeless tobacco use or smoking in 58-year old men. Journal of Internal Medicine 2001; 250: 492–501.
  • Traber MG, van der Vliet A, Reznick AZ, Cross CE. Tobacco-related diseases; is there a role for antioxidant micronutrient supplementation? Clinics in Chest Medicine 2000; 21(1): 173–87.
  • Idris AM, Ahmed HM, Malik MO. Toombak dipping and cancer of the oral cavity in the Sudan: a case control study. Int J Cancer 1995; 63(4): 477–80.
  • Winn DM, Blot WJ, Shy CM, Pickle LW, Toledo A, Fraumeni JF. Snuff dipping and oral cancer among women in the Southern United States. NEJM 1981; 304(13): 745–9.
  • Phukan RK, Zomawia E, Narain K, Hazarika NC, Mahanta J. Tobacco use and stomach cancer in Mizoram, India. Cancer Epidemiol Biomarkers Prev 2005; 14(8): 1892–6.
  • Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who used snuff or chewing tobacco (United States). Cancer Causes Control 2005; 16(4): 347–58.
  • Henley SJ, Connell C, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tobacco Control 2007; 16: 22–8.
  • Slotkin TA. Fetal nicotine or cocaine exposure: which one is worse? Pharmacology and Experimental Therapeutics 1998; 285(3): 931–45.
  • Gupta PC, Sreevidya S. Smokeless tobacco use, birth weight, and gestational age: population-based, prospective cohort study of 1217 women in Mumbai, India. Available from: www.http://bmj.bmjjournals.com/cgi/content/full/328/7455/1538 (Accessed 4/11/2005).
  • England LJ, Levine RJ, Mills JL, Klebanoff MA, Yu KF, Cnattingius S. Adverse pregnancy outcomes in snuff users. Am J Obstet Gynecol 2003; 189(4): 939–43.